Autres langues Ono Pharmaceutical Co., Ltd.

Actions

4528

JP3197600004

Temps Différé Japan Exchange Autres places de cotation 06:17:11 26/04/2024			Varia. 5j.	Varia. 1 janv.
2 291 ^JPY	+0,95 %		+2,35 %	-8,96 %

21/03	ONO Pharmaceuticals, Co, Ltd. annonce que le recrutement est terminé pour le premier volet de l'étude PROSPECT sur le tirabrutinib chez les patients américains atteints de PCNSL en rechute ou réfractaire	CI
14/03	Sibylla Biotech entame une collaboration stratégique de découverte de médicaments avec Ono Pharmaceutical Co. dans le domaine des troubles du système nerveux central	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area	25/04
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers	05/04
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock	29/03
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan	28/03
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	25/03
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25/03
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	22/03
ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL	21/03
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders	15/03
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders	14/03
Sibylla Biotech Enters Strategic Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. in Central Nervous System Disorders	14/03
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	12/03
Ono Pharmaceutical Co., Ltd. Enters into A University-Wide, Research Alliance Agreement with Harvard University	11/03
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101	06/03
Ono Pharmaceutical Announces Status of Acquisition of Own Shares	04/03
Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares	04/03
Tranche Update on Ono Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 25, 2023.	04/03
Ono Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 25, 2023, has closed with 18,732,400 shares, representing 3.88% for ¥49,999.75 million.	01/03
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets	20/02
InveniAI LLC Announces Collaboration with Ono Pharmaceutical for Target Discovery	19/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ono Pharmaceutical Co., Ltd.

Actions

4528

JP3197600004

Autres langues

Filtres